Case Report

Cutaneous metastasis of signet ring cell appendiceal adenocarcinoma: a herald of disease recurrence

Jennifer L. Seyffert1*, Nathan Bibliowicz1, Christopher Wong2, Michael Wangia1

1Department of Dermatology at Kansas City University of Medicine and Biosciences-Advanced Dermatology and Cosmetic Surgery, Dermatology Residency of Orlando, Orlando, FL
2College of Osteopathic Medicine of the Pacific of Western University of Health Sciences, Pomona, CA

Received: 08 January 2020
Revised: 04 March 2020
Accepted: 09 March 2020

*Correspondence:
Dr. Jennifer L. Seyffert,
E-mail: Jennifer.seyffert@adcsclinics.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Signet ring cell appendiceal adenocarcinoma (SRCAA) is a rare entity with poor prognosis and high tendency for metastasis to pelvic lymph nodes, ovaries, and peritoneal surfaces. Despite numerous reports of intra-abdominal metastasis, there have been few reported cases of cutaneous SRCAA metastasis. We report a rare case of SRCAA metastatic to the cutaneous abdominal wall in a 67 years old female, which was first presenting sign of disease recurrence.

Keywords: Metastatic signet ring cell appendiceal adenocarcinoma, Cutaneous metastasis, Signet ring cell, Appendiceal adenocarcinoma

INTRODUCTION

Signet ring cell carcinomas, frequent in the stomach and intestine, are adenocarcinomas with mucus-producing tumor cells. Signet ring cell appendiceal adenocarcinoma (SRCAA) is a rare entity with poor prognosis and high tendency for metastasis to pelvic lymph nodes, ovaries, and peritoneal surfaces.1-6 Despite numerous reports of intra-abdominal metastasis, there have been few reported cases of cutaneous SRCAA metastasis.5 We report a rare case of SRCAA metastatic to the cutaneous abdominal wall in a 67 years old female, which was first presenting sign of disease recurrence.

CASE REPORT

A 67 years old female with a history of stage IV signet ring cell appendiceal adenocarcinoma (SRCAA) presented with an erythematous, malodorous, tender eruption extending from her anterior abdominal wall scar that had been locally spreading over the past 3 months. In 2017, the patient had been initially treated with colectomy with ileostomy, and six cycles of leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX), followed by hyperthermic intraperitoneal chemotherapy (HIPEC). The patient had recurrence and metastatic deposits in her anterior abdominal scar prompting another seven cycles of leucovorin calcium, fluorouracil, and irinotecan (FOLFIRI), followed by radiation to the anterior abdominal wall scar in early 2018. Interval CT and positron emission tomography (PET) scans had remained negative for metastatic disease in the visceral organs, peritoneum, and lymph nodes. Her primary care physician had treated her abdominal rash with a combination of antiviral and antibiotics without improvement.

Upon presentation, physical examination was notable for edematous, erythematous, malodorous nodules coalescing into plaques on the anterior abdomen in the region of her
anterior abdominal surgical scar (Figure 1). There was no
evidence of inguinal lymphadenopathy. A broad
cutaneous shave biopsy was performed which
demonstrated a dermal proliferation of signet ring cells
with abundant mucin and epithelial extension (Figures 2
and 3). Tumor cells were immunoreactive with CDX-2
(Figure 4), AE1/AE3, CK20 (Figure 5), carcinoem-
bryonic antigen (CEA), and epithelial membrane antigen
(EMA) stains; tumor cells were negative for CK7, CK5/6,
P63, GCDFP-15, and S-100. Colloidal iron stain
highlighted intracellular mucin deposition. The histologic
features and immunohistochemical profile in this case
were compatible with cutaneous metastasis of SRCAA.
CEA levels were elevated at 4.7 ng/ml. CT and PET scan
remained negative for any intra-abdominal involvement.
The patient is currently following with oncology.

Figure 1: Erythematous nodules coalescing into
plaques in the region of the patient’s anterior
abdominal surgical scar.

Figure 2: H and E, low power visualization of dermal
proliferation of signet ring cells.

Figure 3: H and E, high power visualization of signet
ring cells with abundant mucin.

Figure 4: Positive CDX-2 immunohistochemical stain.

Figure 5: Positive CK20 immunohistochemical stain.
DISCUSSION

Signet ring cell carcinomas, frequent in the stomach and intestine, are adenocarcinomas with mucus-producing tumor cells. SRCAA is rare, comprising only 4 % of all primary appendiceal neoplasms. SRCAA is a clinically aggressive type of cancer that often spreads to the pelvic lymph nodes, ovaries, and peritoneal surfaces by the time of diagnosis. The most common presentation is right lower quadrant abdominal pain mimicking acute appendicitis. Advanced abdomino-pelvic malignancies can also present as a metastatic umbilical nodule, termed a sister Mary Joseph nodule. There have been cases of reported inheritance of signet ring cell carcinomas caused by mutation of CDH1 gene, which encodes E-cadherin, an important glycoprotein in cell-cell adhesion. Somatic mutations of APC gene have also been reported in gastric signet ring cell carcinoma.

Diagnosis is confirmed with cutaneous biopsy and imaging studies. Histologically, the appearance of signet ring cells result from formation of large vacuoles of mucin that displace the nucleus to the cell’s periphery. Primary cutaneous signet ring cell carcinoma (PCSRC) is a rare entity of suspected sweat gland origin, which stain positively with MNF116, CA15-3, BCA225, GCDPP15, CEA, CA125, and CK20. Given the rarity of PCSRC, it is important to rule out metastatic primary visceral malignancy.

SRCAA is a histopathologically distinct tumor. Reported cases describe tumor cells demonstrating diffuse, strong immunoreactivity against CK20, CDX-2, MUC-2, CEA, and focal immunopositivity for MUC-5AC. CDX-2 is a useful marker to confirm an appendiceal origin; it can be used in conjunction with CK20, MUC-2, and MUC-5AC for confirmation. Imaging studies, such as CT scan, are helpful to identify, but not distinguish SRCAA from other histological types of appendiceal carcinomas. On imaging, spread to adjacent organs is evident in 76 % of SRCAA at presentation compared with the mucinous (63 %) and colonic type (37 %) carcinomas.

The treatment options for metastatic disease include systemic chemotherapy, hyperthermic intraoperative intraperitoneal chemotherapy, cytoreductive surgery with a peritonectomy, and or a combination of the above treatments. It is controversial whether debulking surgery and intraperitoneal chemotherapy are worthwhile for all aggressive, advanced disease cases.

The prognosis is considered very poor, with a 5 years survival rate of 18 %, this is the lowest overall 5 years survival rate of all the subtypes of appendiceal carcinoma. Those who presented with distant metastatic disease had an even lower 5 years survival rate of 7 %.

CONCLUSION

Cutaneous metastasis of SRCAA is rare and may present as the only herald of disease recurrence. Noting the distinction between primary and metastatic sign ring cell carcinomas is of high importance, as the evaluation, management, and prognosis for the two entities are distinct. Given these implications, the dermatologist plays an integral role and should be attentive to these diagnostic possibilities.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES


